Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases
Biomolecules · 25.03.2026 · 16 (4) · 491
DOI: 10.3390/biom16040491 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 25.03.2026. Verfasst von Rui Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou 543002, China. Hauptthemen laut MEDLINE: Signal Transduction, Biological Products, NF-kappa B, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Startup fund for talent introduction and scientific research of Wuzhou University, Scientific research project of Wuzhou University-key project, Start up fund for talent introduction and scientific research of Wuzhou University.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) remain the primary cause of human morbidity and mortality in the world. Inflammation, oxidative stress, and vascular remodeling are the key factors that make CVDs worse. The nuclear factor κB (NF-κB) signaling pathway is a major regulator in the progression of CVDs. NF-κB activates wrongly, induces the secretion of pro-inflammatory cytokines (including TNF-α, IL-6, and IL-1β), and enhances reactive oxygen species (ROS) generation. These accelerate endothelial dysfunction, myocardial damage, and atherosclerotic plaque development. Natural products are structurally diverse, multi-targeted, and low toxicity. They offer a promising way to prevent and treat cardiovascular disease by modulating the NF-κB signaling pathway. This review summarizes the recent studies about using natural products (including flavonoids, terpenoids, alkaloids, polyphenols, and polysaccharides) to treat CVDs through the NF-κB pathway, with a critical analysis of evidence strength according to CVDs indication (atherosclerosis, myocardial ischemia/reperfusion injury, pulmonary arterial hypertension, etc.) and study type (in vitro, in vivo animal, and human clinical research). We detail their molecular mechanisms, such as inhibiting the nuclear translocation of NF-κB p65, downregulating IκB phosphorylation, blocking upstream signaling (e.g., TLR4/MyD88, PI3K/Akt, MAPK), and affecting with other pathways (e.g., Nrf2/HO-1, SIRT1) to reduce inflammation and oxidative stress together. We also detail the effects of these natural products in various CVDs models, including atherosclerosis, hypertension, myocardial ischemia/reperfusion injury, diabetic cardiomyopathy, and pulmonary arterial hypertension, highlighting the characteristics of their treatments. Finally, we discuss the challenges of bringing natural products into the clinic and share some ideas to solve difficulties, with an in-depth critical analysis of the translational bottlenecks (poor bioavailability, unclear structure–activity relationships, incomplete mechanistic elucidation, and lack of large-scale clinical trials) and their underlying causes across different natural product classes. In summary, this review offers new perspectives on developing natural product-based therapies targeting the NF-κB signaling pathway for CVDs. It offers useful references for both preclinical studies and clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou 543002, China.
- Guangxi Liupao Tea Modern Industry College, Wuzhou University, Wuzhou 543002, China.
- Food Science and Technology Program, Department of Life Sciences, Beijing Normal-Hong Kong Baptist University, Zhuhai 519087, China.
ORCID-Profile: Baojun Xu
Förderung
- Startup fund for talent introduction and scientific research of Wuzhou University
- Scientific research project of Wuzhou University-key project
- Start up fund for talent introduction and scientific research of Wuzhou University
Zitieren
APA
Liu, R., Liu, W., Dong, L., Ma, S., & Xu, B. (2026). Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases. Biomolecules, 16(4), 491. https://doi.org/10.3390/biom16040491
Vancouver
Liu R, Liu W, Dong L, Ma S, Xu B. Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases. Biomolecules. 2026;16(4):491. doi:10.3390/biom16040491
BibTeX
@article{Liu2026,
author = {Liu, Rui and Liu, Wencong and Dong, Ling and Ma, Shuang and Xu, Baojun},
title = {Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {4},
pages = {491},
doi = {10.3390/biom16040491}
}
EUVIMED